A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
A phase 2 trial of Osimertinib, Furmonertinib, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07622186 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 150 participants planned, started 2026-07-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB571 for injection, Osimertinib, Furmonertinib, carboplatin, Cisplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-
Shares Sichuan Kelun-Biotech, Osimertinib, Carboplatin, Pembrolizumab.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Furmonertinib, Osimertinib, Cisplatin, Carboplatin.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Osimertinib, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan
Shares Sichuan Kelun-Biotech, Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto
Shares Sichuan Kelun-Biotech, Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Shares Sichuan Kelun-Biotech, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan
Shares Osimertinib, Cisplatin, Carboplatin, Small-cell lung cancer.